Navigation Links
Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
Date:8/23/2007

- Positive Phase 2 Clinical Trial Results from PI-88 in Liver Cancer and

$92.4 million in Raised Capital Highlight the Year -

SYDNEY, Australia, Aug. 23 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today released its financial results for the fiscal year ended 30 June 2007.

Fiscal 2007 Corporate Highlights

* Announced positive results from a Phase 2, 172 patient, post-resection

liver cancer trial for P1-88 that support moving into a multi-national

registration-directed Phase 3 trial;

* Raised a net total of $92.4 million through various fundraising

activities, which provides Progen with additional working capital to fund

the Phase 3 clinical development of PI-88 in post-resection liver cancer,

conduct additional clinical trials of PI-88 in other indications and

further develop other product candidates;

* Completed a royalty-buy-back negotiation with Medigen Biotechnology

Corporation (Medigen) resulting in the conclusion of the Strategic

Alliance between the two companies, which provides Progen with maximum

flexibility and the opportunity to more rapidly develop and commercialise

PI-88;

* Continued efforts on the Company's Phase 2 PI-88 prostate and melanoma

trials with results expected in the first half and second half of calendar

2008, respectively;

* Completed Phase 2 Non-Small Cell Lung Cancer trial with results due by

the end of the third quarter in calendar 2007;

* Received a grant of up to $4.6 million through the Australian

Government's Pharmaceuticals Partnerships Program that will be used

towards PI-88's research and development costs;

* Expanded senior management team and established leading international

clinical advisory board of liver cancer specialists to support the

clinical development and commercialisation of PI-88 in post-resection

liver cancer;

* Selected lead candidates for our drug discovery program focused on

developing inhibitors of heparin binding proteins, and presented animal

data at the American Association of Cancer Research meeting. Progen

expects to submit an Investigational New Drug application to the FDA by

the end of the calendar year 2008.

"This past fiscal year was the most significant and successful in Progen's history," said Justus Homburg, Chief Executive Officer of Progen Pharmaceuticals. "Our positive Phase 2 results for PI-88 in liver cancer, combined with our considerable fundraising efforts, have effectively positioned us to initiate our Phase 3 Trial during this calendar year and continue aggressively pursuing the development, registration and commercialisation of PI-88. At the completion of the trial, we expect to have a registration package for PI-88 in over a dozen countries."

Fiscal 2007 Financial Results:

Progen's operating loss for the year ended 30 June 2007 was $22.5 million, as compared to $7.6 million in 2006. The operating loss from continuing operations, excluding the non-recurring compensation of $11.7 million paid to Medigen in 2007, amounted to $10.7 million, as compared to $7.0 million in 2006, representing a 53.6 percent increase from last year. Of the $11.7 million paid to Medigen, $11.4 million was non-cash and included equity payments and the return of our investment in Medigen.

The operating loss includes expenses of $2.2 million, as compared to $369,000 in 2006 for costs associated with preparations for the Phase 3 development of PI-88, including regulatory, additional animal studies and manufacturing.

Fiscal 2007 revenue and other income totalled $3.8 million, as compared to $2.8 million in 2006, a 33.9 percent increase. This increase was due to a 41.2 percent increase in revenue from a previously received Australian government grant, and a 58.3 percent increase in interest income due to increased funds on deposit following the Company's capital raisings.

* All figures quoted above are in Australian dollars.

About Progen: Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer.

Progen Information:

Linton Burns

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: lintonb@progen-pharma.com

Noreen Dillane

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: noreend@progen-pharma.com

Media and Investor Relations Australia:

Rebecca Piercy

Buchan Consulting

T: +61 2 9237 2800 / 0422 916 422

E: rpiercy@bcg.com.au

Rebecca Wilson

Buchan Consulting

T: +61 417 382 391

E: rwilson@bcg.com.au

Media Relations USA:

Robert D. Stanislaro

FD

T: 212-850-5657

E: robert.stanislaro@fd.com

Investor Relations USA:

Evan Smith

FD

T: 212-850-5606

E: evan.smith@fd.com


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
(Date:5/10/2017)... Ill. , May 10, 2017 Radiology ... today; unfortunately its costs have also spiraled to the ... being sent to radiology than ever before as the ... diagnosis.  For a patient with lower back pain an ... no anatomical reason for pain, resulting in entirely different ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... background. Understanind and choosing the most appropriate instruments for research and understanding the ... research finding. This webinar will focus on innovations in stereo microscopy for brightfield ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
(Date:5/24/2017)... , ... May 24, 2017 ... ... the female reproductive tract in which the endometrial lining of the uterus ... inflammation and pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after ... Public Television. “Informed” brings the public important topics from all aspects of life, and ... feet and issues surrounding feet and ankles. , Podiatry is essential to people’s overall ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), ... announced today that its iClinic V12.2 solution has achieved approval from National Center ... introduced PCMH 2017 standards which emphasize team-based care with a significant focus on ...
Breaking Medicine News(10 mins):